Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
RxSight, Inc. (RXST)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/18/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results|
Docs:
|
"RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Sales $ 20,810 $ 11,360 $ 38,299 $ 20,301 Cost of sales 8,795 6,572 15,919 11,752 Gross profit 12,015 4,788 22,380 8,549 Operating expenses: Selling, general and administrative 18,239 14,388 34,492 28,008 Research and development 7,401 6,192 14,608 12,911 Total operating expenses 25,640 20,580 49,100 40,919 Loss from operations Other income , net: Interest expense Interest and other income 1,777 196 3,168 242 Loss on extinguishment of term loan — — Loss before income taxes Income tax expense 26 — 27 4 Net loss $ $ $ $ Other comprehensive income Unrealized gain on short-term investments 19 Foreign currency translation gain 1 3..." |
|
| 07/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...|
Docs:
|
"LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT dated as of June 30, 2023 among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 , as collateral agent , the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender, OXFORD FINANCE CREDIT FUND II LP, by its manager Oxford Finance Advisors, LLC, with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 , OXFORD FINANCE CREDIT FUND III LP, by its manager Oxford Finance Advisors, LLC, with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 , and RXSIGHT, INC., a Delaware corporation with offices located at 100 Columbia, Ali..." |
|
| 06/05/2023 |
SC 13D/A
| Longitude Capital Partners II, LLC reports a 7.5% stake in RXSIGHT, INC. |
| 06/01/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended March 31, 2023 2022 Sales $ 17,489 $ 8,942 Cost of sales 7,123 5,181 Gross profit 10,366 3,761 Operating expenses: Selling, general and administrative 16,255 13,620 Research and development 7,208 6,719 Total operating expenses 23,463 20,339 Loss from operations Other income , net: Interest expense Interest and other income 1,392 46 Loss before income taxes Income tax expense — 4 Net loss $ $ Other comprehensive income Unrealized gain on short-term investments 84 Foreign currency translation gain 2 Total other comprehensive income 86 Comprehensive loss $ $ Net loss per share: Basic & diluted $ $ Weighted-average shares used in computing net loss per share: Attributable to common stock..." |
|
| 04/20/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/20/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/20/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/06/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Sales $ 16,088 $ 8,427 $ 49,005 $ 22,593 Cost of sales 8,666 5,558 27,677 18,076 Gross profit 7,422 2,869 21,328 4,517 Operating expenses: Selling, general and administrative 15,731 11,619 58,665 32,805 Research and development 6,681 5,916 25,981 24,499 Total operating expenses 22,412 17,535 84,646 57,304 Loss from operations Other income , net: Change in fair value of warrants — — — 2,717 Expiration of warrant — — — 5,018 Interest expense Interest and other income 836 11 1,517 54 Loss before income taxes Income tax expense 5 — 9 8 Net loss $ $ $ $ Other comprehensive loss Unrealized gain on short-term investments 28 Foreig..." |
|
| 02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 3.3% stake in RxSight, Inc. |
| 02/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement, by and between the Company and BofA Securities, Inc",
"Opinion of Wilson Sonsini Goodrich & Rosati, P.C",
"RxSight, Inc. Announces Pricing of Public Offering of Common Stock Aliso Viejo, Calif. - February 7, 2023 - RxSight, Inc. , an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 4,000,000 shares of its common stock at a price to the public of $12.50 per share. RxSight has granted the underwriter a 30-day option to purchase up to an additional 600,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by RxSight. Before deducting the underwriting discount and estimated offering expenses payable by RxSight, RxSight expects to receive gross proceeds of approximat..." |
|
| 02/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits Interactive Data |
| 11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
8-K
| Quarterly results|
Docs:
|
"RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Sales $ 12,615 $ 5,786 $ 32,917 $ 14,167 Cost of sales 7,259 4,445 19,011 12,519 Gross profit 5,356 1,341 13,906 1,648 Operating expenses: Selling, general and administrative 14,926 9,076 42,934 21,189 Research and development 6,388 5,377 19,300 18,583 Total operating expenses 21,314 14,453 62,234 39,772 Loss from operations Other income , net: Change in fair value of warrants — 1,503 — 2,717 Expiration of warrant — — — 5,018 Interest expense Interest and other income 439 11 681 44 Loss before income taxes Income tax expense — 4 6 Net loss $ $ $ $ Other comprehensive loss Unrealized gain on short-term investments 55..." |
|
| 08/15/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/12/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/08/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"RxSight, Inc. Files Shelf Registration Statement and Announces $50 Million At-The-Market Equity Offering Program Aliso Viejo, Calif. - August 8, 2022 - RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it has filed a $200 million shelf registration statement on Form S-3 with the Securities and Exchange Commission . Once declared effective by the SEC, the shelf registration statement would permit the Company to sell, from time to time, up to $200 million in aggregate value of its common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are approp..." |
|
| 08/08/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results|
Docs:
|
"RxSIGHT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Sales $ 11,360 $ 4,897 $ 20,301 $ 8,381 Cost of sales 6,572 5,709 11,752 8,074 Gross profit 4,788 8,549 307 Operating expenses: Selling, general and administrative 14,388 6,502 28,008 12,113 Research and development 6,192 6,563 12,911 13,206 Total operating expenses 20,580 13,065 40,919 25,319 Loss from operations Other income , net: Change in fair value of warrants — 1,214 — 1,214 Expiration of warrant — — — 5,018 Interest expense Interest and other income 196 15 242 32 Loss before income taxes Income tax expense 0 3 4 10 Net loss $ $ $ $ Other comprehensive loss Unrealized gain on short-term investments 3 Foreign currency t..." |
|
| 07/11/2022 |
8-K
| Quarterly results |
| 06/02/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/05/2022 |
8-K
| Quarterly results |
| 04/21/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|
|
|